Hero image with Pittsburgh background pittplusme.org/study/1245

STUDY BASICS

Have you been diagnosed with ovarian cancer that has come back after your previous treatment? If so, you may be eligible to participate in a study to help investigators evaluate the safety of a new anticancer drug, called ribociclib (LEE011). Involves receiving the study drug along with chemotherapy for 24 weeks. You will then receive the study drug by itself (maintenance dose).


IRB:
  STUDY19030437 - HCC 18-006, Phase I Trial of Ribociclib (Ribociclib (LEE011)) with Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

Age Range
AGE:   18 and up

 
Gender List
SEX ASSIGNED AT BIRTH:   Female

Location LOCATION: 
Magee-Women’s Hospital of UPMC
Compensation COMPENSATION: 

NONE

Phone Number PHONE NUMBER:
1-866-438-8230
SHARE STUDY
Printer Printer   Email A FriendEmail A Friend   ShareShare   TweetTweet   Linked-InLinked-In
Search Icon pittplusme.org/study/1245
OR
Phone Number PHONE NUMBER:
1-866-438-8230

PittPlusMe.org 1-866-438-8230 PittPlusMe@pitt.edu
@PittPlusMe share tweet